

STREAMLINE THE EXCEPTION PROCESS FOR JUVMO

An exception letter requests coverage for a nonformulary or NDC-blocked medicine when it is medically necessary. Follow the steps below to help ensure your request is complete and avoid delays or denials.

3 EASY STEPS TO FOLLOW



1 Confirm payer requirements

- Review the payer's exception, prior authorization, or appeal requirements
- Check what documentation, forms, and timelines are needed



2 Write a Letter of Medical Necessity (LMN), which may include:

- Patient name, DOB, and member ID
- Requested medication and dosing strength
- Medical diagnosis and brief clinical summary
- Why the standard covered option is not appropriate
- Physician's supporting statement and clinical justification
- How patients may benefit (eg, improved off time, quality of life, work balance, motor symptoms, etc)
- Prior therapy failures, intolerances, and/or contraindications
- Relevant chart notes, labs, imaging, or test results
- Denial letter or payer reference, if applicable
- Provider contact info and signature

Scan to Access
Letter Templates



Scan or visit
[JuvmoHCP.com/about-juvmo-complete](https://juvmohcp.com/about-juvmo-complete)
to access LMN or Appeals templates
for monotherapy and adjunctive use



3 Submit the request

- Complete any forms required by the payer
- Include the LMN, along with all supporting documentation
 - Patient chart notes or Medical Records, including lab test results, past treatment history, and proof of medical condition
 - Prescription information, including the exact name, strength, and dose of the drug, in addition to the name and phone number of pharmacy
- Submit through the payer's required channel
- Keep a copy and record the submission date, confirmation number, and any follow-up deadline
- Note urgency: If clinically appropriate, consider noting and clearly describing in the submission any symptoms that are severe, rapidly worsening, or significantly affecting the safety and/or daily functioning of the patient and follow any payer requirements for requesting expedited review



For support with the exception process, contact your Field Reimbursement Manager.

Please see Indication and Important Safety Information for JUVMO on the following page.

Please see accompanying full [Prescribing Information](https://www.rxabbvie.com/pdf/juvmo_pi.pdf) or visit https://www.rxabbvie.com/pdf/juvmo_pi.pdf.

INDICATION

JUVMO is indicated for the treatment of Parkinson's disease in adults.

IMPORTANT SAFETY INFORMATION

Warnings and Precautions

Hypotension/Orthostatic Hypotension: Patients with Parkinson's disease (PD) may have an impaired capacity to respond to an orthostatic challenge. In clinical studies and clinical experience, dopaminergic medications appear to impair the systemic regulation of blood pressure, resulting in hypotension and/or orthostatic hypotension, especially during dose escalation. Patients with PD treated with JUVMO (tavapadon) should be monitored for signs and symptoms of hypotension/orthostatic hypotension, especially during dose escalation, and should be informed of this risk.

Impulse Control/Compulsive Behaviors: Patients may experience intense urges while on JUVMO. Because patients may not recognize these behaviors as abnormal, it is important for prescribers to ask patients or their caregivers specifically about the development of new or increased gambling urges, sexual urges, uncontrolled spending, binge or compulsive eating, or other urges while on JUVMO. Consider reducing the dose or discontinuing JUVMO if a patient develops such urges.

Hallucinations and Psychotic-like Behavior: Medications for the treatment of PD, including JUVMO, can have effects on thinking and behavior. Age appears to increase the risk of hallucinations in patients taking JUVMO. The risk of hallucination may be increased when JUVMO is co-administered with strong CYP3A inhibitors during the maintenance phase. Consider the risks and benefits prior to initiating treatment with JUVMO in patients with a major psychotic disorder because of the risk of exacerbating psychosis. Consider stopping JUVMO if hallucinations or psychotic-like behaviors occur.

Dyskinesia: JUVMO may cause or exacerbate pre-existing dyskinesia. Consider decreasing the dosage of JUVMO or other dopaminergic medications if dyskinesia occurs.

Adverse Reactions

The most common adverse reactions ($\geq 5\%$) for JUVMO without levodopa were nausea, headache, dizziness, fatigue, dysgeusia, vomiting, dry mouth, and anxiety.

The most common adverse reactions ($\geq 5\%$) for JUVMO with levodopa were nausea, dyskinesia, dizziness, headache, hallucinations, and orthostatic hypotension.

Drug Interactions

Strong CYP3A Inducers: Avoid use with JUVMO. **Strong and moderate CYP3A inhibitors:** avoid use with JUVMO during titration; JUVMO dosage modification is recommended during maintenance. **Moderate CYP3A Inducers:** JUVMO dosage modification is recommended during titration and maintenance. **Consult the full Prescribing Information for JUVMO** for more information on drug interactions and recommended dosage modifications.

Dosage Forms and Strengths

JUVMO is available as 5 mg, 10 mg, and 15 mg tablets, as well as 0.25 mg and 1 mg tablets contained in a Titration Pack.

Please see accompanying full [Prescribing Information](#) or visit https://www.rxabbvie.com/pdf/juvmo_pi.pdf.